Next-generation exome sequencing provides a cost-effective and rapid approach to identifying pathogenic variants in the COL2A1 gene responsible for type II collagenopathies, which is important for genetic counseling and can reduce the risk of recurrent cases in families and improve the clinical follow-up of patients. The gene discussed is COL2A1; the disease is type 2 collagenopathy.